Mode
Text Size
Log in / Sign up
N/A N=211 Treatment

Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers

Periampullary Cancers With Obstructive Jaundice · Pancreas Head Cancer · Bile Duct Cancer · Ampulla of Vater Cancer

Enrolled (actual)
211
Serious AEs
24.6%
Results posted
Jun 2014
Primary outcome: Primary: Incidence of Infectious Complications After Biliary Drainage — 11; 5 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
biliary drainage (Procedure)
Age
Adult, Older Adult · 20+ yrs
Sex
All
Sponsor
Seoul National University Hospital
Primary completion
May 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Incidence of Infectious Complications After Biliary Drainage
11; 5
SECONDARY
Change in Total Serum Bilirubin After Drainage
0.7; 0.6
SECONDARY
Total Hospital Cost During Admission After Biliary Drainage
16.0; 17.0

Summary

Preoperative biliary drainage methods include percutaneous transhepatic biliary drainage (PTBD), endoscopic nasobiliary drainage (ENBD), and endoscopic retrograde biliary drainage (ERBD). Endoscopic biliary drainages often induce peritumoral inflammation and it increase difficulties in determining a proper resection margin. The purpose of this study is to compare the clinicopathological outcomes according to the methods of preoperative biliary drainage in periampullary cancers causing obstructive jaundice, and to find out a proper biliary drainage method.

Eligibility Criteria

Inclusion Criteria

  • patient who have periampullary tumors causing obstructive jaundice
  • patient age: ≥20 and ≤85
  • resectable state of disease
  • no history of previous chemotherapy or radiotherapy
  • patients without uncontrollable severe cardiovascular, respiratory disease
  • Karnofsky performance scale ≥70
  • informed consent

Exclusion Criteria

  • patients with distant metastasis or locally advanced disease with major vascular invasion
  • duodenal cancer
  • biliary drainage before randomization
  • previous chemotherapy or radiotherapy
  • uncontrollable active infection except cholangitis
  • severe comorbid disease (cardiac, pulmonary, cerebrovascular)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01134276). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search